Morgan Stanley analyst Sean Laaman has maintained their bullish stance on EXEL stock, giving a Buy rating on October 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman’s rating is based on the competitive performance of Exelixis’s zanza in comparison to existing therapies. The data indicates that zanza shows an improved overall survival rate over regorafenib and is competitive with LONSURF plus bevacizumab, with a median overall survival of 10.9 months. This positions zanza as a strong contender in the market, especially as standard of care treatments tend to improve over time.
Additionally, the safety profile of zanza appears manageable, with no new safety signals identified, although there is a noted increase in hypertension compared to competitors. Despite this, the efficacy results are considered adequate and align with investor expectations, supporting the Buy rating. The improvements in progression-free survival and overall survival, consistent across various subgroups, further reinforce the positive outlook for Exelixis’s stock.
In another report released on October 18, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $44.00 price target.